Partner with Interleukin Genetics

Applying Critical Genetic Insights to Drug Development

As a leader in the field of DNA-based risk assessment for diseases associated with inflammation and metabolic diseases, Interleukin Genetics has developed a strong IP portfolio and works with some of the industry’s leading researchers to commercialize meaningful genetic tests for the personalized healthcare market.

Learn about how Interleukin Genetics can help your drug development program by harnessing our knowledge and research capabilities in the field of genetics to accelerate commercialization success.

Partnership with Interleukin Genetics allows:

Clinical Trial Patient Selection – Genetic biomarkers that guide selection of patients in clinical trials to increase the likelihood of improved trial efficacy outcome and improve risk-benefit ratio.

Companion Diagnostics – Develop simple diagnostics that enable targeted use of a therapeutic to increase commercial success.

Drug Rescue and Repositioning – Integrate pharmacogenetics into drug development processes carries potential to rescue drugs in late-stage clinical testing when endpoints were not met or were weak.

Strengths of Interleukin Genetics include:

Validated technology and Commercial products
Robust and clinically validated genetic biomarkers
High throughput sample processing with rapid SNP testing platform capabilities
CLIA approved laboratory
Experienced team with expertise in the genetics of inflammatory/autoimmune and metabolic disease
Strong IP portfolio; 20 US patents issued, 21 new patent applications filed

Learn about how Interleukin Genetics can help your drug development program by harnessing our knowledge and research capabilities in the field of genetics to accelerate commercialization success. For more information on collaboration with Interleukin Genetics, please contact us at partnering@ilgenetics.com.